On June 8, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, reported it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will provide strategic, scientific, and clinical program updates anchored by TransCode’s recently-initiated Phase 2a clinical trial of TTX-MC138 — the Company’s lead antagomiR program — in ctDNA-positive colorectal cancer, alongside portfolio and investment thesis updates across its development pipeline. A recording of the webcast will be made available on the Company’s website following the event.
Date:
Thursday, June 18, 2026
Time:
10:00 -11:15 a.m. Eastern Time
Format:
Live webcast, open access
Registration:
Will be made available on www.transcodetherapeutics.com as of June 11, 2026
Replay:
Webcast recording available on the Company’s website following the event
The webcast will cover:
TTX-MC138 Phase 2a clinical development, including trial design and strategic path forward
Pipeline and development strategy across the Company’s other candidates and platforms
Capital strategy, financial position, and long-term investment thesis
Featured speakers will include:
Guest: Keith Flaherty, MD — Director of Clinical Research, Massachusetts General Hospital Cancer Center; Professor of Medicine, Harvard Medical School; Member, TransCode Scientific Advisory Board
Philippe P Calais, PharmD, PhD — Chief Executive Officer and Chairman of the Board, TransCode Therapeutics
Dan Vlock, MD — Consulting Oncology Clinician, TransCode Therapeutics
Zdravka Medarova, PhD — Co-Founder and Chief Scientific Officer, TransCode Therapeutics
Louis Brenner, MD — Consulting Strategic Advisor, TransCode Therapeutics
Michel Janicot, PhD — Consulting Head of Translational Science, TransCode Therapeutics
"With TTX-MC138 now beginning enrollment in Phase 2a, and with two additional platform assets advancing on capital-disciplined timelines, TransCode is at a meaningful inflection point. This webcast is an opportunity to share for the first time in our Company’s history the scientific depth behind our programs, review the clinical data that supported our decision to move into the Phase 2a trial, and articulate the investment thesis underlying a three-platform pipeline. We look forward to engaging with our investors and the investment community."
(Press release, TransCode Therapeutics, JUN 8, 2026, View Source [SID1234666489])